bullish
Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal
807 Views29 May 2019 14:01
Just ahead of the launch of Hansoh Pharma's book building for its USD 1bn IPO, news reported today that Hansoh inked a license-in agreement with...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (8 Jun 2019) -ESR Cayman, Shanghai Henlius, Edvantage, JH Education08 Jun 2019
- ECM Weekly (1 Jun 2019) - Hansoh, China East Edu, GSX, CSSC (HK) Shipping, China Tobacco01 Jun 2019
- Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End30 May 2019
- Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation23 May 2019
- Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer21 May 2019
x